Instalimb Funding Boosts AI Prosthetics Innovation

Instalimb, a pioneer in leveraging artificial intelligence and 3D printing for prosthetic and orthotic solutions, has successfully closed a significant funding round. The investment was led by Orthomos Investment, the financial arm of the Orthomos Group, signaling strong confidence in Instalimb's innovative approach to assistive device manufacturing. This capital infusion is set to accelerate the company's expansion and further refine its digital workflow.

The company's proprietary technology integrates 3D computer-aided design (CAD) with advanced 3D printing and machine learning algorithms. This end-to-end digital manufacturing process dramatically streamlines the creation of prosthetic legs. Instalimb's model has demonstrated remarkable efficiency gains, reducing production costs and delivery timelines to less than a tenth of conventional methods. Furthermore, it amplifies a prosthetist's manufacturing capacity by over tenfold, addressing critical bottlenecks in the sector.

With a proven track record, Instalimb has already supplied over 9,000 3D-printed prosthetic legs and related products through its direct sales clinics in the Philippines and India. Its technology has also been adopted by more than ten organizations, including prominent names like ALIMCO and BMVSS Jaipur Foot, underscoring the scalability and effectiveness of its digital manufacturing framework. This widespread adoption highlights the global demand for more accessible and affordable prosthetic solutions.

Beyond the direct investment, Instalimb has entered into a strategic basic agreement with Alcare, another entity within the Orthomos Group. This collaboration will focus on co-developing adjustable prosthetic sockets and exploring the creation of orthotic and welfare equipment utilizing digital technologies. A key objective is to jointly pursue business expansion opportunities within the Japanese market, potentially through a franchising model.

This strategic partnership and funding are pivotal for Instalimb as it aims to introduce its solutions, initially developed and proven in emerging markets, to the sophisticated Japanese healthcare sector. The company's success in reducing costs and improving patient access in the Global South positions it uniquely to address unmet needs in developed markets as well. The prosthetics and orthotics market, valued at over $8 billion globally and projected to grow at a CAGR of around 5%, is ripe for technological disruption.

Instalimb's journey began in March 2017, and this latest funding round builds upon its previous successes. By March 2025, the company had secured approximately ¥1.1 billion in a Series B extension, bringing its total cumulative funding to around ¥2.13 billion. This sustained investor interest reflects the growing recognition of AI and additive manufacturing's transformative potential in healthcare, particularly in creating personalized and cost-effective medical devices.